Found: 13
Select item for more details and to access through your institution.
Differential inhibition of HIV-1 cell binding and HIV-1-induced syncytium formation by low molecular weight sulphated polysaccharides.
- Published in:
- 1990
- By:
- Publication type:
- journal article
rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Optimization and validation of the HIV-1 neutralizing antibody assay in A3R5 cells.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV - depending on IgG dose.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-56550-4
- By:
- Publication type:
- Article
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
- Published in:
- 1996
- By:
- Publication type:
- journal article
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.
- Published in:
- Mucosal Immunology (1933-0219), 2013, v. 6, n. 4, p. 692, doi. 10.1038/mi.2012.107
- By:
- Publication type:
- Article
Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.
- Published in:
- Mucosal Immunology (1933-0219), 2009, v. 2, n. 6, p. 536, doi. 10.1038/mi.2009.103
- By:
- Publication type:
- Article
CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody.
- Published in:
- Clinical & Experimental Immunology, 1992, v. 90, n. 3, p. 383
- By:
- Publication type:
- Article